Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 1001: What is considered a toxic serum level of lithium?

A. 0.6
B. 12
C. 2.6 (Correct Answer)
D. <0.6

Explanation: **2.6 mEq/L** - **Lithium toxicity** is generally considered to occur when serum lithium levels are above **1.5 mEq/L** with severe toxicity typically seen at levels above **2.5 mEq/L**. - At a level of **2.6 mEq/L**, patients are at high risk for significant neurological symptoms such as seizures, coma, and even death. *0.6 mEq/L* - A serum lithium level of **0.6 mEq/L** is within the normal therapeutic range, which is typically between **0.6 and 1.2 mEq/L**. - At this concentration, lithium is generally effective for bipolar disorder and other conditions with minimal risk of toxicity. *12 mEq/L* - A serum lithium level of **12 mEq/L** would represent an **extremely severe and likely fatal level of toxicity**, far beyond typical therapeutic or even severely toxic ranges. - Survival at such a high concentration would be highly improbable, as it would cause irreversible organ damage and profound central nervous system depression. *<0.6 mEq/L* - A serum lithium level of **less than 0.6 mEq/L** is considered subtherapeutic, meaning it is unlikely to be effective in treating bipolar disorder or other conditions. - While not toxic, such a low level would indicate a lack of therapeutic benefit and potential for symptom recurrence.

Question 1002: Which of the following is/are hepatotoxic anesthetic agent(s)?

A. Halothane
B. Both Chloroform and Halothane (Correct Answer)
C. None of the above
D. Chloroform

Explanation: ***Both Chloroform and Halothane*** - Both agents are well-established hepatotoxins used historically in anesthesia - **Chloroform** causes direct hepatotoxicity through centrilobular necrosis due to reactive metabolites (CYP2E1-mediated) - **Halothane** causes halothane hepatitis, a rare but potentially fatal immune-mediated hepatotoxicity (occurs in 1:10,000-35,000 exposures) - This is the **most complete answer** as it includes all hepatotoxic agents listed *Halothane* - This is medically correct - halothane is indeed hepatotoxic - However, this is **incomplete** as it omits chloroform, another hepatotoxic anesthetic agent in the options - When multiple correct agents are listed, the most comprehensive answer is preferred *Chloroform* - This is medically correct - chloroform is indeed hepatotoxic - However, this is **incomplete** as it omits halothane, another hepatotoxic anesthetic agent in the options - Chloroform was historically used but abandoned due to hepatotoxicity and cardiac arrhythmias *None of the above* - This is incorrect as both chloroform and halothane have well-documented hepatotoxic effects - Both agents can cause liver damage ranging from transient enzyme elevation to fulminant hepatic failure

Question 1003: Pralidoxime acts in organophosphorus poisoning by:

A. Regenerating Cholinesterase (Correct Answer)
B. Inhibiting cholinesterase
C. Cholinergic action
D. Blocking muscarinic receptors

Explanation: ***Regenerating Cholinesterase*** - Pralidoxime (2-PAM) is an **oxime** that works by **reactivating acetylcholinesterase** inhibited by organophosphates [1], [2], [3]. - It does this by binding to the phosphorous atom of the organophosphate, thereby cleaving the bond between the organophosphate and the enzyme [2], [3]. - Most effective when given **early**, before "aging" of the enzyme-inhibitor complex occurs [1], [3]. *Inhibiting cholinesterase* - This is the mechanism of action of **organophosphates** themselves, not pralidoxime [3]. - Pralidoxime's role is to **reverse this inhibition**. *Cholinergic action* - Pralidoxime itself does not have a direct cholinergic action; its effect is indirect by **restoring functioning cholinesterase** [2]. - Medications like **atropine** are used in organophosphate poisoning to block the effects of excessive acetylcholine, which is a cholinergic action [1]. *Blocking muscarinic receptors* - This is the mechanism of **atropine**, which is co-administered with pralidoxime in organophosphate poisoning [1]. - Atropine blocks the muscarinic effects of acetylcholine accumulation, while pralidoxime reactivates the enzyme [3]. - Pralidoxime works by **enzyme reactivation**, not receptor blockade [2].

Question 1004: Which of the following statements about orphan drugs is true?

A. No aid is offered to pharmaceutical companies for developing orphan drugs
B. Treatment of common disease in a resourceful country
C. Rifabutin is not an orphan drug
D. Diagnosis, prevention, or treatment of rare diseases or conditions (Correct Answer)

Explanation: ***Diagnosis, prevention, or treatment of rare diseases or conditions*** - Orphan drugs are specifically developed for **rare diseases or conditions** affecting a small percentage of the population. - Due to the limited patient pool, there is often **insufficient commercial incentive** for pharmaceutical companies to develop these drugs without special support. *No aid is offered to pharmaceutical companies for developing orphan drugs* - This statement is **incorrect**; governments and regulatory bodies offer significant incentives, such as **tax credits**, **fee waivers**, and **extended market exclusivity**, to encourage orphan drug development. - These incentives are crucial to offset the high costs of research and development for drugs that will serve a small market. *Rifabutin is not an orphan drug* - This statement is **incorrect**; **Rifabutin** is indeed an **orphan drug** used in the treatment of **Mycobacterium avium complex (MAC) infection**, which is a rare, severe opportunistic infection in immunocompromised individuals. - It received orphan drug designation due to the rarity of the condition it targets. *Treatment of common disease in a resourceful country* - This statement is **incorrect** because orphan drugs are specifically for **rare diseases**, not common ones. - The concept of "resourceful country" is irrelevant to the definition of an orphan drug, as the focus is on the prevalence of the disease rather than geographic or economic factors.

Question 1005: Peliosis hepatis is associated with all of the following except?

A. Analgesics (Correct Answer)
B. OC pills
C. Danazol
D. Anabolic steroids

Explanation: ***Analgesics*** - There is **no established association** between the use of common analgesics (like NSAIDs or acetaminophen) and the development of **peliosis hepatis**. - Peliosis hepatis is typically linked to **specific medications, infections, or underlying conditions**, not general pain relievers. *Anabolic steroids* - **Anabolic androgenic steroids** are well-known to cause peliosis hepatis, leading to the formation of **blood-filled cysts** in the liver. - This adverse effect is often dose-dependent and can result in **hepatic dysfunction** or rupture. *OC pills* - **Oral contraceptives (OCs)**, particularly those with high estrogen content, have been associated with an increased risk of peliosis hepatis. - The hormonal effects can lead to **sinusoidal dilatation** and the formation of peliosis. *Danazol* - **Danazol**, a synthetic androgen, is another medication strongly linked to the development of peliosis hepatis. - Its mechanism involves similar hepatic vascular changes seen with other **androgenic steroids**.

Question 1006: Which antihypertensive agent is used topically to treat alopecia and should be used with caution in young females?

A. Hydralazine
B. Prazosin
C. Minoxidil (Correct Answer)
D. Indapamide

Explanation: ***Minoxidil*** - **Minoxidil** is a direct **vasodilator** that, when applied topically, stimulates hair growth and is commonly used for **androgenetic alopecia**. - It should be used with caution in young females due to the potential for **hypertrichosis** (unwanted hair growth) outside the scalp if not applied precisely. *Hydralazine* - **Hydralazine** is a direct-acting **vasodilator** primarily used orally or intravenously to treat moderate to severe hypertension and heart failure. - It is not used topically for alopecia and acts differently on blood vessels than minoxidil. *Prazosin* - **Prazosin** is an **alpha-1 adrenergic blocker** used orally to treat hypertension, benign prostatic hyperplasia, and sometimes PTSD. - It is not indicated for topical use in alopecia. *Indapamide* - **Indapamide** is a **thiazide-like diuretic** that acts by increasing the excretion of sodium and water, primarily used to treat hypertension and edema. - It has no known role in the topical treatment of alopecia.

Question 1007: Sirolimus is more likely than cyclosporine to cause which of the following?

A. Osteoporosis
B. Renal insufficiency
C. Thrombocytopenia (Correct Answer)
D. Hypertension

Explanation: ***Thrombocytopenia*** - **Sirolimus** frequently causes **myelosuppression**, leading to **thrombocytopenia** and leukopenia. - While both sirolimus and cyclosporine can have side effects, **thrombocytopenia** is a more prominent and distinguishing adverse effect of sirolimus. *Hypertension* - **Cyclosporine** is well-known for causing **hypertension** due to its effect on the renin-angiotensin-aldosterone system and endothelial dysfunction. - While sirolimus can cause hypertension, it is generally less pronounced compared to cyclosporine. *Osteoporosis* - **Corticosteroids** are the primary immunosuppressants associated with **osteoporosis** due to their effects on bone metabolism. - Neither sirolimus nor cyclosporine is a major direct cause of osteoporosis. *Renal insufficiency* - **Cyclosporine** is distinctively associated with **nephrotoxicity**, leading to acute and chronic **renal insufficiency** through vasoconstriction and tubular damage. - While sirolimus can impact renal function indirectly or in combination with calcineurin inhibitors, cyclosporine's direct nephrotoxic effect is more significant.

Question 1008: A patient on amphotericin B develops hypokalemia with a potassium level of 2.3 mEq/L. What is the appropriate K+ supplementation required for this patient?

A. 40 mEq over 24 hours
B. 80 mEq over 24 hours (Correct Answer)
C. 60 mEq over 24 hours
D. 100-120 mEq over 24 hours

Explanation: ***80 mEq over 24 hours***- For a potassium level of 2.3 mEq/L (moderate to severe hypokalemia), **80 mEq over 24 hours** represents appropriate aggressive replacement while maintaining safety.- This dose accounts for both the **existing deficit** and **ongoing renal potassium wasting** caused by amphotericin B, which impairs renal tubular function.- Standard guidelines recommend **60-80 mEq daily** for moderate to severe hypokalemia, divided into multiple doses with continuous cardiac monitoring.- Higher doses risk **rebound hyperkalemia** and cardiac complications [1]; replacement should be titrated based on serial potassium measurements.*40 mEq over 24 hours*- This dosage is insufficient for correcting a potassium level of 2.3 mEq/L, particularly with **ongoing drug-induced renal losses**.- It may be appropriate for mild hypokalemia (3.0-3.5 mEq/L) or maintenance therapy, but not for this clinical scenario.*60 mEq over 24 hours*- While this represents a reasonable starting dose for moderate hypokalemia, it may be **insufficient** given the severity (K+ 2.3 mEq/L) and ongoing losses from amphotericin B.- This dose might require escalation after reassessment of potassium levels.*100-120 mEq over 24 hours*- This dose **exceeds standard safe replacement protocols** and risks causing rebound hyperkalemia and cardiac arrhythmias [1].- Maximum safe infusion rates are typically **10-20 mEq/hour** (up to 40 mEq/hour only in critical situations with intensive monitoring).- Such aggressive replacement is not recommended in standard clinical practice for this scenario.

Question 1009: A patient on atracurium develops seizures due to accumulation of which substance?

A. Atracurium acid
B. Laudanosine (Correct Answer)
C. Cisatracurium
D. Histamine

Explanation: ***Laudanosine*** - Atracurium is metabolized into **laudanosine**, a **neurotoxic metabolite** that can accumulate, particularly in patients with renal or hepatic dysfunction, leading to **seizures** and central nervous system excitation. - Due to its potential for neurotoxicity, atracurium is often replaced by **cisatracurium**, which produces less laudanosine. *Cisatracurium* - **Cisatracurium** is an isomer of atracurium that is also metabolized via **Hofmann elimination** but produces significantly **less laudanosine**. - It is preferred in patients with **renal or hepatic impairment** due to its reduced potential for metabolite accumulation and neurotoxicity. *Atracurium acid* - Atracurium acid is one of the **inactive metabolites** of atracurium, along with laudanosine. - Unlike laudanosine, atracurium acid is **not neurotoxic** and does not contribute to seizure activity. *Histamine* - Atracurium can cause an **immediate release of histamine**, leading to transient hypotension, flushing, and bronchospasm, especially with rapid bolus injection. - While histamine release is an adverse effect of atracurium, it is **not directly responsible for seizure activity**.

Question 1010: Which of the following is NOT a known cause of gynecomastia?

A. Isoniazid (INH)
B. Cimetidine
C. Digitalis
D. Pyrazinamide (Correct Answer)

Explanation: ***Pyrazinamide*** - **Pyrazinamide** is an **antituberculosis drug** known for causing **hyperuricemia** and **hepatotoxicity**, but it is **not commonly associated with gynecomastia**. - Its mechanism of action does not directly interfere with **hormone balance** in a way that typically leads to breast tissue enlargement. *Isoniazid (INH)* - **Isoniazid** can cause **gynecomastia** in some patients, possibly due to its effects on **liver metabolism** and subsequent alterations in **estrogen-androgen balance**. - It interferes with **vitamin B6 metabolism**, which can indirectly affect **steroid hormone synthesis** and breakdown. *Cimetidine* - **Cimetidine** is a **histamine H2-receptor antagonist** that can cause gynecomastia by acting as an **antiandrogen**. - It directly binds to **androgen receptors**, blocking the action of androgens and leading to an imbalance in the **estrogen-androgen ratio**. *Digitalis* - **Digitalis** (digoxin) is a **cardiac glycoside** that has a **steroid-like structure** and can exhibit **estrogenic effects**. - These estrogenic properties can lead to increased breast tissue growth and **gynecomastia** in male patients, especially with long-term use.

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free